Brokerages predict that Zimmer Biomet Holdings Inc (NYSE:ZBH) will announce earnings of $2.26 per share for the current quarter, Zacks Investment Research reports. Eleven analysts have made estimates for Zimmer Biomet’s earnings, with the highest EPS estimate coming in at $2.29 and the lowest estimate coming in at $2.24. Zimmer Biomet posted earnings per share of $2.18 in the same quarter last year, which suggests a positive year over year growth rate of 3.7%. The business is expected to announce its next quarterly earnings results before the market opens on Tuesday, February 4th.
On average, analysts expect that Zimmer Biomet will report full-year earnings of $7.83 per share for the current financial year, with EPS estimates ranging from $7.80 to $7.86. For the next fiscal year, analysts anticipate that the company will post earnings of $8.30 per share, with EPS estimates ranging from $8.23 to $8.42. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Zimmer Biomet.
Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, November 5th. The medical equipment provider reported $1.77 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.75 by $0.02. Zimmer Biomet had a negative net margin of 1.14% and a positive return on equity of 13.71%. The business had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter last year, the company earned $1.63 earnings per share. The firm’s revenue was up 3.0% on a year-over-year basis.
Several equities research analysts recently weighed in on ZBH shares. Needham & Company LLC increased their target price on shares of Zimmer Biomet from $170.00 to $187.00 and gave the company a “strong-buy” rating in a research note on Thursday, December 19th. Piper Jaffray Companies upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their target price for the company from $140.00 to $170.00 in a research note on Tuesday, January 7th. BTIG Research upgraded shares of Zimmer Biomet from a “neutral” rating to a “buy” rating and set a $158.00 target price for the company in a research note on Monday, October 7th. Zacks Investment Research upgraded shares of Zimmer Biomet from a “sell” rating to a “hold” rating and set a $149.00 target price for the company in a research note on Sunday, November 3rd. Finally, Piper Sandler upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their target price for the company from $140.00 to $170.00 in a research note on Tuesday, January 7th. One analyst has rated the stock with a sell rating, five have issued a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $154.35.
Shares of NYSE ZBH traded down $1.71 during mid-day trading on Friday, hitting $147.80. The company had a trading volume of 736,860 shares, compared to its average volume of 746,189. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.17 and a quick ratio of 0.54. The business’s 50-day simple moving average is $149.09 and its 200-day simple moving average is $139.66. Zimmer Biomet has a 12 month low of $105.35 and a 12 month high of $151.70. The firm has a market cap of $30.75 billion, a P/E ratio of -301.63, a PEG ratio of 2.53 and a beta of 1.15.
The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.65%. The ex-dividend date of this dividend is Thursday, December 26th. Zimmer Biomet’s dividend payout ratio is 12.57%.
In other Zimmer Biomet news, insider Aure Bruneau sold 15,171 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $146.78, for a total transaction of $2,226,799.38. 0.72% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Allworth Financial LP increased its holdings in shares of Zimmer Biomet by 65.0% during the third quarter. Allworth Financial LP now owns 203 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 80 shares in the last quarter. Evoke Wealth LLC acquired a new stake in shares of Zimmer Biomet during the third quarter worth approximately $37,000. Bridger Capital Management LLC acquired a new stake in shares of Zimmer Biomet during the third quarter worth approximately $39,000. Usca Ria LLC acquired a new stake in shares of Zimmer Biomet during the third quarter worth approximately $39,000. Finally, Sound Income Strategies LLC acquired a new stake in shares of Zimmer Biomet during the fourth quarter worth approximately $47,000. 87.41% of the stock is owned by institutional investors.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Featured Story: Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.